Word

GC

Status

Registered

Status Code

700

Status Date

Tuesday, August 11, 2020

Serial Number

79241700

Registration Number

6121018

Registration Date

Tuesday, August 11, 2020

Mark Type

3000

Filing Date

Thursday, May 17, 2018

Published for Opposition

Tuesday, May 26, 2020

Trademark Owner History

Green Cross Holdings Corporation - Original Registrant

Classifications

5 Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Medicines for humans, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; medicated plasters; vaccines; biological preparations for medical or veterinary purposes, namely, biological preparations used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; biological preparations for medical or veterinary purposes, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors

35 Retail store services featuring pharmaceutical preparations for the treatment of cells; retail store services featuring medical instruments; retail store services featuring medical apparatus; retail store services featuring biological preparations for medical purposes; retail store services featuring medical genetic analyzer; retail and wholesale store services featuring pharmaceutical preparations; import-export agency services; retail store services featuring electromedical diagnostic instruments; wholesale store services featuring pharmaceutical preparations for the treatment of cells; wholesale store services featuring medical instruments; wholesale store services featuring medical apparatus; wholesale store services featuring biological preparations for medical purposes; wholesale store services featuring medical genetic analyzer; wholesale store services featuring electromedical diagnostic instruments; all the foregoing excluding services in the field of industrial, institutional, commercial and janitorial equipment and supplies

44 Medical services, namely, the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow for medical preventive, diagnostic and treatment purposes; medical examination services; health clinic services, namely, medical clinics; analysis of human tissues for medical diagnosis purposes and treatment; medical consultancy for selecting appropriate medicines; human tissue bank services; medical services, namely, clinical pathology examination; cord blood bank services; health center services; medical and pharmaceutical consultancy; medical and health care services; pharmacy services, namely, dispensing of pharmaceuticals; consultancy and information services relating to the dispensing of pharmaceutical products; dispensing of pharmaceuticals; preparation and dispensing of medications; information services relating to utilization of medical products in connection with the provision of medical services; medical and health services relating to DNA, genetics and genetic testing; managed health care services

10 Medical apparatus and instruments for use in performing biopsies; medical testing apparatus for medical purposes, namely, medical apparatus for testing DNA and RNA samples; medical diagnostic apparatus and instruments for immunodiagnosis and molecular diagnosis; electromedical diagnostic instruments for immunodiagnosis and molecular diagnosis; apparatus for use in medical analysis, namely, medical apparatus for blood test; medical health signal measuring instruments for monitoring vital signs; wireless bio-signal measuring instruments for medical purposes, namely, biofeedback sensors; precision sensors for medical use, namely, heart rhythm sensors, respiratory sensors and biofeedback sensors; laser machining tools for medical use, namely, lasers for surgical and medical use; genetic testing apparatus, namely, apparatus for DNA and RNA testing for medical purposes

42 Research and development of vaccines and medicines; conducting clinical studies of medicines for medical research purposes; clinical research in the nature of performing biopsies for medical research; product research and development of medical products; conducting technical project studies, namely, engineering services in the nature of technical project planning and design engineering of medical products; testing, inspection or research of pharmaceuticals; scientific research relating to biology; scientific research in the field of genetic engineering; research and development of technology for biotechnology; scientific research in the fields of biomedicine; laboratory research in the field of biology; product development of cell therapy products; drug discovery services; research and development in the pharmaceutical and biotechnology fields; scientific research in the field of gene analysis; medical studies, namely, medical laboratory services; research and development of technology for medicinal chemical manufacturing; medical research services relating to clinical data

The mark consists of a stylized rounded cross with the top and right arms in red fading toward the middle to orange then to yellow, and the left and lower arms in green; to the right of the cross are the letters "GC" in deep blue.
The color(s) red, orange, yellow, green and deep blue is/are claimed as a feature of the mark.

Trademark Events

Dec 26, 2020

Final Decision Transaction Processed By Ib

Dec 3, 2020

Final Disposition Notice Sent To Ib

Dec 3, 2020

Final Disposition Processed

Nov 11, 2020

Final Disposition Notice Created, To Be Sent To Ib

Aug 11, 2020

Registered-Principal Register

Jun 12, 2020

Notification Processed By Ib

Jun 12, 2020

Changes/Corrections After Pub Approval Entered

Jun 11, 2020

Assigned To Petition Staff

May 26, 2020

Official Gazette Publication Confirmation E-Mailed

May 26, 2020

Published For Opposition

May 11, 2020

Teas Post Publication Amendment Received

May 6, 2020

Notification Of Possible Opposition Sent To Ib

May 6, 2020

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

May 6, 2020

Notification Of Notice Of Publication E-Mailed

Apr 21, 2020

Law Office Publication Review Completed

Apr 13, 2020

Approved For Pub - Principal Register

Apr 13, 2020

Examiner's Amendment Entered

Apr 13, 2020

Notification Of Examiners Amendment E-Mailed

Apr 13, 2020

Examiners Amendment E-Mailed

Apr 13, 2020

Examiners Amendment -Written

Apr 2, 2020

Previous Allowance Count Withdrawn

Mar 20, 2020

Notification Of Possible Opposition - Processed By Ib

Mar 10, 2020

Withdrawn From Pub - Og Review Query

Mar 4, 2020

Notification Of Possible Opposition Sent To Ib

Mar 4, 2020

Notification Of Possible Opposition Created, To Be Sent To Ib

Feb 26, 2020

Law Office Publication Review Completed

Feb 19, 2020

Approved For Pub - Principal Register

Feb 19, 2020

Examiner's Amendment Entered

Feb 19, 2020

Notification Of Examiners Amendment E-Mailed

Feb 19, 2020

Examiners Amendment E-Mailed

Feb 19, 2020

Examiners Amendment -Written

Feb 19, 2020

Previous Allowance Count Withdrawn

Feb 19, 2020

Withdrawn From Issue - Managing Attorney Request

Jan 14, 2020

Official Gazette Publication Confirmation E-Mailed

Jan 14, 2020

Published For Opposition

Jan 10, 2020

Notification Processed By Ib

Dec 25, 2019

Notification Of Possible Opposition Sent To Ib

Dec 25, 2019

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Dec 25, 2019

Notification Of Notice Of Publication E-Mailed

Dec 10, 2019

Approved For Pub - Principal Register

Dec 6, 2019

Teas/Email Correspondence Entered

Dec 6, 2019

Correspondence Received In Law Office

Dec 2, 2019

Teas Response To Office Action Received

Jul 30, 2019

Notification Of Non-Final Action E-Mailed

Jul 30, 2019

Non-Final Action E-Mailed

Jul 30, 2019

Non-Final Action Written

Jul 23, 2019

Letter Of Protest Evidence Forwarded

May 30, 2019

Notification Of Letter Of Suspension E-Mailed

May 30, 2019

Letter Of Suspension E-Mailed

May 30, 2019

Suspension Letter Written

May 8, 2019

Teas/Email Correspondence Entered

May 8, 2019

Correspondence Received In Law Office

May 8, 2019

Assigned To Lie

May 1, 2019

Teas Response To Office Action Received

Apr 22, 2019

Attorney/Dom.Rep.Revoked And/Or Appointed

Apr 22, 2019

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Nov 24, 2018

Refusal Processed By Ib

Nov 2, 2018

Non-Final Action Mailed - Refusal Sent To Ib

Nov 2, 2018

Refusal Processed By Mpu

Oct 19, 2018

Non-Final Action (Ib Refusal) Prepared For Review

Oct 18, 2018

Non-Final Action Written

Oct 13, 2018

Application Filing Receipt Mailed

Oct 9, 2018

Assigned To Examiner

Oct 9, 2018

New Application Office Supplied Data Entered

Sep 27, 2018

Sn Assigned For Sect 66a Appl From Ib